Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase I/II, Open-label, Dose Escalation and Expansion, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Patients With Advanced Non-Hodgkin Lymphoma.

NCT05205161 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05205161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05205161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase I/II, Open-label, Dose Escalation and Expansion, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Patients With Advanced Non-Hodgkin Lymphoma.
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Terminated
Start date
July 5, 2022
Completion date
August 17, 2023
Enrollment
7 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma